Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Emtricitabine

Molecular formula C8H10FN3O3S Molecular weight 247.25 CAS Registry No 143491-57-0 Merck Index 13,3597 [Pg.215]

Mobile phase MeOH 40 mM pH 2.5 potassium phosphate buffer 5.5 94.5 [Pg.215]

Schinazi, R.P. Boudinot, P.D. Ibrahim, S.S. Manning, C. McClure, H.M. Liotta, D.C. Pharmacokinetics and metabolism of racemic 2, 3 -dideoxy-5-fluoro-3 -thiacytidine in rhesus monkeys, Antimi- [Pg.215]

Sample preparation Extract cells twice with 4 mL portions of MeOH water 60 40 at - 70° overnight, centrifuge at 2000 g for 10 min. Evaporate the methanol from a 500 xL aliquot under a stream of nitrogen, adjust the volume to 200 xL with water, inject a 180 xL aliquot. [Pg.215]

Flow rate 1 Injection volume 180 Detector Radioactivity ( H) [Pg.215]


Tenofovir in its prodrug form tenofovir, disoproxil fumarate (TDF), is indicated in the treatment of HIV infections (AIDS). It is administered as a single oral dose of 300 mg per day. When combined with emtricitabine and efavirenz, TDF has proven to be more efhcacious than the standard combination therapy of combivir (azidothymidine plus lamivudine) and efavirenz (Gallant et al. 2006) and less prone to cause adverse side effects (Pozniak et al. 2006 De Clercq 2007b). [Pg.69]

For the treatment of AIDS, TDF is now available in three commercial preparations, as such (Viread ), in combmation with emtricitabine (Truvada ) and m combination with emtricitabme and efavirenz (Atripla ). The latter represents a three-drugs-in-once combination piU, which has become available for the treatment of AIDS since July 2006. The different milestones mat marked the development and ultimate commercialization of Atripla (m 2006) smce the original identification of adefovir as an antiretroviral agent (m 1986) have been previously reviewed (De Clercq 2006, 2007a-c). [Pg.70]

At present there are seven NRTIs, which have been formally approved for the treatment of AIDS 3 -azido-2, 3 -dideoxythymidine (AZT, zidovudine), 2, 3 -dideoxyinosine (ddl, didanosine), 2, 3 -dideoxycytidine (ddC, zalcitabine), 2, 3 -didehydro-2, 3 -dideoxythymidine (d4T, stavudine), (—)-L-3 -thia-2, 3 -dideoxycytidine (3TC, lamivudine), cyclopentenyl V -cyclopropylaminopurine (abacavir, ABC), and (—)-L-5-fluoro-3 -thia-2, 3 -dideoxycytidine ((—)FTC, emtricitabine) (De Clercq 2004a) (Fig. 3). [Pg.73]

Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E (2001) Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (ETC), J Virol 75 4771 779... [Pg.315]

Zidovudine Didanosine Stavudine Lamivudine Abacavir Tenofovir Emtricitabine Nevirapine Efavirenz TMC125 Saquinavir Indinavir Lopinavir Fosamprenavir Atazanavir Tipranavir Darunavir Raltegravir Elvitegravir Enluvirtide Maraviroc Vicriviroc Bevirimat... [Pg.335]

Tenofovir + Emtricitabine Zidovudine + Lamivudine Abacavir + Lamivudine Efavirenz or Nevirapine Lopinavir/r or Atazanavir/r or Eosamprenavir/r or Saquinavir/r... [Pg.336]

Efavirenz and (didanosine or abacavir or stavudine) and (lamivudine or emtricitabine)... [Pg.1259]

Atazanavir or fosamprenavir or nelfinavir or saquinavir/ ritonavir, and zidovudine or stavudine or tenofovir or abacavir or didanosine, and lamivudine or emtricitabine... [Pg.1259]

Triple NRTI therapy is recommended only when a first-line or alternative first-line therapy with either an NNRTI-based or Pi-based regimen cannot be used. Abacavir plus zidovudine plus lamivudine is the only regimen approved by the DHHS. The following triple nucleoside therapy combinations have shown poor or limited efficacy, and should be avoided abacavir plus tenofovir plus lamivudine (or emtricitabine), and didanosine plus tenofovir plus lamivudine (or emtricitabine). [Pg.1259]

Drugs that should not be combined due to overlapping toxi-cities include amprenavir oral solution plus ritonavir oral solution, atazanavir plus indinavir (due to enhanced hyperbilirubinemia), and any combination of didanosine, stavudine, and zalcitabine. Emtricitabine and lamivudine should not be combined because of their similar chemical structures, and antagonism can result when lamivudine is combined with zalcitabine, or stavudine is combined with zidovudine. [Pg.1259]

TC, lamivudine ABC, abacavir APV, amprenavir AST, aspartate aminotransferase ALT, alanine aminotransferase ATV, atazanavir CBC, complete blood cell count D/C, discontinue ddl, didano-sine d4T, stavudine EFV, efavirenz FTC, emtricitabine P1BV, hepatitis B virus F1CV, hepatitis C vims HIV, human immunodeficiency virus IDV, indinavir IV, intravenous LFT, liver function tests LPV/r, lopinavir + ritonavir NNRTI, nonnucleoside reverse transcriptase inhibitor NRTI, nucleoside reverse transcriptase inhibitor NVP, nevirapine PI, protease inhibitor PT, prothrombin time T.bili, total bilirubin TDF, tenofovir disoproxiI fumarate TPV, tipranavir ULN, upper limit of normal ZDV, zidovudine. [Pg.1271]

Current recommendations for treating HIV infection advocate a minimum of three antiretroviral agents. The typical regimen consists of two NtRTIs and either a ritonavir-boosted PI or NNRTI. The dual NtRTI backbone should include tenofovir plus emtricitabine (coformulated as Truvada) or zidovudine plus lamivudine (coformulated as Combivir). Abacavir plus lamivudine is an alternative. Recommended initial NtRTIs include atazana-vir-ritonavir, lopinavir-ritonavir, or fosamprenavir-ritonavir. Efavirenz is the recommended NNRTI except for women who plan to become pregnant or who do not have adequate contraception. [Pg.454]

Tablets 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate (equivalent to 245 mg tenofovir disoproxil) (Rx)... Tablets 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate (equivalent to 245 mg tenofovir disoproxil) (Rx)...

See other pages where Emtricitabine is mentioned: [Pg.198]    [Pg.3]    [Pg.47]    [Pg.76]    [Pg.81]    [Pg.83]    [Pg.291]    [Pg.339]    [Pg.1255]    [Pg.1258]    [Pg.1259]    [Pg.1259]    [Pg.1261]    [Pg.1262]    [Pg.1263]    [Pg.1266]    [Pg.1267]    [Pg.1275]    [Pg.1275]    [Pg.1275]    [Pg.1276]    [Pg.268]    [Pg.271]    [Pg.587]    [Pg.614]    [Pg.453]    [Pg.455]    [Pg.507]    [Pg.589]    [Pg.616]    [Pg.63]    [Pg.83]    [Pg.1880]   
See also in sourсe #XX -- [ Pg.63 , Pg.69 , Pg.70 , Pg.73 ]

See also in sourсe #XX -- [ Pg.146 ]

See also in sourсe #XX -- [ Pg.407 ]

See also in sourсe #XX -- [ Pg.585 ]

See also in sourсe #XX -- [ Pg.283 , Pg.342 ]

See also in sourсe #XX -- [ Pg.424 ]

See also in sourсe #XX -- [ Pg.356 ]

See also in sourсe #XX -- [ Pg.146 ]

See also in sourсe #XX -- [ Pg.383 , Pg.384 , Pg.386 ]

See also in sourсe #XX -- [ Pg.28 ]

See also in sourсe #XX -- [ Pg.21 ]

See also in sourсe #XX -- [ Pg.325 ]

See also in sourсe #XX -- [ Pg.132 ]

See also in sourсe #XX -- [ Pg.206 ]

See also in sourсe #XX -- [ Pg.610 ]

See also in sourсe #XX -- [ Pg.705 ]

See also in sourсe #XX -- [ Pg.243 ]

See also in sourсe #XX -- [ Pg.542 ]

See also in sourсe #XX -- [ Pg.27 ]

See also in sourсe #XX -- [ Pg.675 ]

See also in sourсe #XX -- [ Pg.146 ]

See also in sourсe #XX -- [ Pg.1215 , Pg.1216 ]

See also in sourсe #XX -- [ Pg.319 ]

See also in sourсe #XX -- [ Pg.123 , Pg.125 ]

See also in sourсe #XX -- [ Pg.213 ]

See also in sourсe #XX -- [ Pg.215 ]

See also in sourсe #XX -- [ Pg.416 ]

See also in sourсe #XX -- [ Pg.168 ]




SEARCH



Atripla (efavirenz, emtricitabine

Didanosine Emtricitabine

Efavirenz, emtricitabine, tenofovir

Efavirenz, emtricitabine, tenofovir Atripla)

Emtricitabine Famciclovir

Emtricitabine Foods

Emtricitabine NRTIs

Emtricitabine Nucleoside reverse transcriptase inhibitors

Emtricitabine Stavudine

Emtricitabine Zidovudine

Emtricitabine adverse effects

Emtricitabine dosing

Emtricitabine drug interactions

Emtricitabine monophosphate

Emtricitabine pharmacokinetics

Emtricitabine preparation

Emtricitabine resistance

Emtricitabine triphosphate

Emtricitabine/tenofovir disoproxil fumarate

Human immunodeficiency virus emtricitabine

Reverse transcriptase inhibitors emtricitabine

Tenofovir/emtricitabine

© 2024 chempedia.info